CHAPTER 1:INTRODUCTION
1.1.Report description
1.2.Key market segments
1.3.Key benefits to the stakeholders
1.4.Research Methodology
1.4.1.Secondary research
1.4.2.Primary research
1.4.3.Analyst tools and models
CHAPTER 2:EXECUTIVE SUMMARY
2.1.Key findings of the study
2.2.CXO Perspective
CHAPTER 3:MARKET OVERVIEW
3.1.Market definition and scope
3.2.Key findings
3.2.1.Top investment pockets
3.3.Porter’s five forces analysis
3.4.Top player positioning
3.5.Market dynamics
3.5.1.Drivers
3.5.2.Restraints
3.5.3.Opportunities
3.6.COVID-19 Impact Analysis on the market
3.7.Patent Landscape
CHAPTER 4: PSORIASIS THERAPEUTICS MARKET, BY DRUG CLASS
4.1 Overview
4.1.1 Market size and forecast
4.2 TNF-alpha Inhibitors
4.2.1 Key market trends, growth factors and opportunities
4.2.2 Market size and forecast, by region
4.2.3 Market analysis by country
4.3 Interleukin Inhibitors
4.3.1 Key market trends, growth factors and opportunities
4.3.2 Market size and forecast, by region
4.3.3 Market analysis by country
4.3.4 Interleukin Inhibitors Psoriasis Therapeutics Market by Distribution Channel
4.3.4.1 Hospital Pharmacies Market size and forecast, by region
4.3.4.2 Drug Stores and Retail Pharmacies Market size and forecast, by region
4.3.4.3 Online Providers Market size and forecast, by region
4.4 Others
4.4.1 Key market trends, growth factors and opportunities
4.4.2 Market size and forecast, by region
4.4.3 Market analysis by country
CHAPTER 5: PSORIASIS THERAPEUTICS MARKET, BY TYPE
5.1 Overview
5.1.1 Market size and forecast
5.2 Plaque Psoriasis
5.2.1 Key market trends, growth factors and opportunities
5.2.2 Market size and forecast, by region
5.2.3 Market analysis by country
5.3 Psoriatic Arthritis
5.3.1 Key market trends, growth factors and opportunities
5.3.2 Market size and forecast, by region
5.3.3 Market analysis by country
5.4 Others
5.4.1 Key market trends, growth factors and opportunities
5.4.2 Market size and forecast, by region
5.4.3 Market analysis by country
CHAPTER 6: PSORIASIS THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION
6.1 Overview
6.1.1 Market size and forecast
6.2 Oral
6.2.1 Key market trends, growth factors and opportunities
6.2.2 Market size and forecast, by region
6.2.3 Market analysis by country
6.3 Parenteral
6.3.1 Key market trends, growth factors and opportunities
6.3.2 Market size and forecast, by region
6.3.3 Market analysis by country
6.4 Topical
6.4.1 Key market trends, growth factors and opportunities
6.4.2 Market size and forecast, by region
6.4.3 Market analysis by country
CHAPTER 7: PSORIASIS THERAPEUTICS MARKET, BY REGION
7.1 Overview
7.1.1 Market size and forecast
7.2 North America
7.2.1 Key trends and opportunities
7.2.2 North America Market size and forecast, by Drug Class
7.2.2.1 North America Interleukin Inhibitors Psoriasis Therapeutics Market by Distribution Channel
7.2.3 North America Market size and forecast, by Type
7.2.4 North America Market size and forecast, by Route of Administration
7.2.5 North America Market size and forecast, by country
7.2.5.1 U.S.
7.2.5.1.1 Market size and forecast, by Drug Class
7.2.5.1.2 Market size and forecast, by Type
7.2.5.1.3 Market size and forecast, by Route of Administration
7.2.5.2 Canada
7.2.5.2.1 Market size and forecast, by Drug Class
7.2.5.2.2 Market size and forecast, by Type
7.2.5.2.3 Market size and forecast, by Route of Administration
7.2.5.3 Mexico
7.2.5.3.1 Market size and forecast, by Drug Class
7.2.5.3.2 Market size and forecast, by Type
7.2.5.3.3 Market size and forecast, by Route of Administration
7.3 Europe
7.3.1 Key trends and opportunities
7.3.2 Europe Market size and forecast, by Drug Class
7.3.2.1 Europe Interleukin Inhibitors Psoriasis Therapeutics Market by Distribution Channel
7.3.3 Europe Market size and forecast, by Type
7.3.4 Europe Market size and forecast, by Route of Administration
7.3.5 Europe Market size and forecast, by country
7.3.5.1 Germany
7.3.5.1.1 Market size and forecast, by Drug Class
7.3.5.1.2 Market size and forecast, by Type
7.3.5.1.3 Market size and forecast, by Route of Administration
7.3.5.2 France
7.3.5.2.1 Market size and forecast, by Drug Class
7.3.5.2.2 Market size and forecast, by Type
7.3.5.2.3 Market size and forecast, by Route of Administration
7.3.5.3 UK
7.3.5.3.1 Market size and forecast, by Drug Class
7.3.5.3.2 Market size and forecast, by Type
7.3.5.3.3 Market size and forecast, by Route of Administration
7.3.5.4 Italy
7.3.5.4.1 Market size and forecast, by Drug Class
7.3.5.4.2 Market size and forecast, by Type
7.3.5.4.3 Market size and forecast, by Route of Administration
7.3.5.5 Spain
7.3.5.5.1 Market size and forecast, by Drug Class
7.3.5.5.2 Market size and forecast, by Type
7.3.5.5.3 Market size and forecast, by Route of Administration
7.3.5.6 Rest of Europe
7.3.5.6.1 Market size and forecast, by Drug Class
7.3.5.6.2 Market size and forecast, by Type
7.3.5.6.3 Market size and forecast, by Route of Administration
7.4 Asia-Pacific
7.4.1 Key trends and opportunities
7.4.2 Asia-Pacific Market size and forecast, by Drug Class
7.4.2.1 Asia-Pacific Interleukin Inhibitors Psoriasis Therapeutics Market by Distribution Channel
7.4.3 Asia-Pacific Market size and forecast, by Type
7.4.4 Asia-Pacific Market size and forecast, by Route of Administration
7.4.5 Asia-Pacific Market size and forecast, by country
7.4.5.1 Japan
7.4.5.1.1 Market size and forecast, by Drug Class
7.4.5.1.2 Market size and forecast, by Type
7.4.5.1.3 Market size and forecast, by Route of Administration
7.4.5.2 China
7.4.5.2.1 Market size and forecast, by Drug Class
7.4.5.2.2 Market size and forecast, by Type
7.4.5.2.3 Market size and forecast, by Route of Administration
7.4.5.3 India
7.4.5.3.1 Market size and forecast, by Drug Class
7.4.5.3.2 Market size and forecast, by Type
7.4.5.3.3 Market size and forecast, by Route of Administration
7.4.5.4 Australia
7.4.5.4.1 Market size and forecast, by Drug Class
7.4.5.4.2 Market size and forecast, by Type
7.4.5.4.3 Market size and forecast, by Route of Administration
7.4.5.5 South Korea
7.4.5.5.1 Market size and forecast, by Drug Class
7.4.5.5.2 Market size and forecast, by Type
7.4.5.5.3 Market size and forecast, by Route of Administration
7.4.5.6 Rest of Asia-Pacific
7.4.5.6.1 Market size and forecast, by Drug Class
7.4.5.6.2 Market size and forecast, by Type
7.4.5.6.3 Market size and forecast, by Route of Administration
7.5 LAMEA
7.5.1 Key trends and opportunities
7.5.2 LAMEA Market size and forecast, by Drug Class
7.5.2.1 LAMEA Interleukin Inhibitors Psoriasis Therapeutics Market by Distribution Channel
7.5.3 LAMEA Market size and forecast, by Type
7.5.4 LAMEA Market size and forecast, by Route of Administration
7.5.5 LAMEA Market size and forecast, by country
7.5.5.1 Brazil
7.5.5.1.1 Market size and forecast, by Drug Class
7.5.5.1.2 Market size and forecast, by Type
7.5.5.1.3 Market size and forecast, by Route of Administration
7.5.5.2 Saudi Arabia
7.5.5.2.1 Market size and forecast, by Drug Class
7.5.5.2.2 Market size and forecast, by Type
7.5.5.2.3 Market size and forecast, by Route of Administration
7.5.5.3 South Africa
7.5.5.3.1 Market size and forecast, by Drug Class
7.5.5.3.2 Market size and forecast, by Type
7.5.5.3.3 Market size and forecast, by Route of Administration
7.5.5.4 Rest of LAMEA
7.5.5.4.1 Market size and forecast, by Drug Class
7.5.5.4.2 Market size and forecast, by Type
7.5.5.4.3 Market size and forecast, by Route of Administration
CHAPTER 8: COMPANY LANDSCAPE
8.1. Introduction
8.2. Top winning strategies
8.3. Product Mapping of Top 10 Player
8.4. Competitive Dashboard
8.5. Competitive Heatmap
8.6. Key developments
CHAPTER 9: COMPANY PROFILES
9.1 Abbvie Inc.
9.1.1 Company overview
9.1.2 Company snapshot
9.1.3 Operating business segments
9.1.4 Product portfolio
9.1.5 Business performance
9.1.6 Key strategic moves and developments
9.2 Amgen Inc.
9.2.1 Company overview
9.2.2 Company snapshot
9.2.3 Operating business segments
9.2.4 Product portfolio
9.2.5 Business performance
9.2.6 Key strategic moves and developments
9.3 Bausch Health Companies Inc.
9.3.1 Company overview
9.3.2 Company snapshot
9.3.3 Operating business segments
9.3.4 Product portfolio
9.3.5 Business performance
9.3.6 Key strategic moves and developments
9.4 Eli Lilly and Company
9.4.1 Company overview
9.4.2 Company snapshot
9.4.3 Operating business segments
9.4.4 Product portfolio
9.4.5 Business performance
9.4.6 Key strategic moves and developments
9.5 Johnson and Johnson
9.5.1 Company overview
9.5.2 Company snapshot
9.5.3 Operating business segments
9.5.4 Product portfolio
9.5.5 Business performance
9.5.6 Key strategic moves and developments
9.6 LEO Pharma
9.6.1 Company overview
9.6.2 Company snapshot
9.6.3 Operating business segments
9.6.4 Product portfolio
9.6.5 Business performance
9.6.6 Key strategic moves and developments
9.7 Novan Inc. (EPI Health LLC)
9.7.1 Company overview
9.7.2 Company snapshot
9.7.3 Operating business segments
9.7.4 Product portfolio
9.7.5 Business performance
9.7.6 Key strategic moves and developments
9.8 Novartis AG
9.8.1 Company overview
9.8.2 Company snapshot
9.8.3 Operating business segments
9.8.4 Product portfolio
9.8.5 Business performance
9.8.6 Key strategic moves and developments
9.9 Pfizer Inc.
9.9.1 Company overview
9.9.2 Company snapshot
9.9.3 Operating business segments
9.9.4 Product portfolio
9.9.5 Business performance
9.9.6 Key strategic moves and developments
9.10 Viatris Inc. (Mylan NV)
9.10.1 Company overview
9.10.2 Company snapshot
9.10.3 Operating business segments
9.10.4 Product portfolio
9.10.5 Business performance
9.10.6 Key strategic moves and developments
TABLE 1. GLOBAL PSORIASIS THERAPEUTICS MARKET, BY DRUG CLASS, 2021-2031 ($MILLION)
TABLE 2. PSORIASIS THERAPEUTICS MARKET, FOR TNF-ALPHA INHIBITORS, BY REGION, 2021-2031 ($MILLION)
TABLE 3. PSORIASIS THERAPEUTICS MARKET FOR TNF-ALPHA INHIBITORS, BY COUNTRY, 2021-2031 ($MILLION)
TABLE 4. PSORIASIS THERAPEUTICS MARKET, FOR INTERLEUKIN INHIBITORS, BY REGION, 2021-2031 ($MILLION)
TABLE 5. PSORIASIS THERAPEUTICS MARKET FOR INTERLEUKIN INHIBITORS, BY COUNTRY, 2021-2031 ($MILLION)
TABLE 6. GLOBAL INTERLEUKIN INHIBITORS PSORIASIS THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
TABLE 7. PSORIASIS THERAPEUTICS MARKET, FOR HOSPITAL PHARMACIES, BY REGION, 2021-2031 ($MILLION)
TABLE 8. PSORIASIS THERAPEUTICS MARKET, FOR DRUG STORES AND RETAIL PHARMACIES, BY REGION, 2021-2031 ($MILLION)
TABLE 9. PSORIASIS THERAPEUTICS MARKET, FOR ONLINE PROVIDERS, BY REGION, 2021-2031 ($MILLION)
TABLE 10. PSORIASIS THERAPEUTICS MARKET, FOR OTHERS, BY REGION, 2021-2031 ($MILLION)
TABLE 11. PSORIASIS THERAPEUTICS MARKET FOR OTHERS, BY COUNTRY, 2021-2031 ($MILLION)
TABLE 12. GLOBAL PSORIASIS THERAPEUTICS MARKET, BY TYPE, 2021-2031 ($MILLION)
TABLE 13. PSORIASIS THERAPEUTICS MARKET, FOR PLAQUE PSORIASIS, BY REGION, 2021-2031 ($MILLION)
TABLE 14. PSORIASIS THERAPEUTICS MARKET FOR PLAQUE PSORIASIS, BY COUNTRY, 2021-2031 ($MILLION)
TABLE 15. PSORIASIS THERAPEUTICS MARKET, FOR PSORIATIC ARTHRITIS, BY REGION, 2021-2031 ($MILLION)
TABLE 16. PSORIASIS THERAPEUTICS MARKET FOR PSORIATIC ARTHRITIS, BY COUNTRY, 2021-2031 ($MILLION)
TABLE 17. PSORIASIS THERAPEUTICS MARKET, FOR OTHERS, BY REGION, 2021-2031 ($MILLION)
TABLE 18. PSORIASIS THERAPEUTICS MARKET FOR OTHERS, BY COUNTRY, 2021-2031 ($MILLION)
TABLE 19. GLOBAL PSORIASIS THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2031 ($MILLION)
TABLE 20. PSORIASIS THERAPEUTICS MARKET, FOR ORAL, BY REGION, 2021-2031 ($MILLION)
TABLE 21. PSORIASIS THERAPEUTICS MARKET FOR ORAL, BY COUNTRY, 2021-2031 ($MILLION)
TABLE 22. PSORIASIS THERAPEUTICS MARKET, FOR PARENTERAL, BY REGION, 2021-2031 ($MILLION)
TABLE 23. PSORIASIS THERAPEUTICS MARKET FOR PARENTERAL, BY COUNTRY, 2021-2031 ($MILLION)
TABLE 24. PSORIASIS THERAPEUTICS MARKET, FOR TOPICAL, BY REGION, 2021-2031 ($MILLION)
TABLE 25. PSORIASIS THERAPEUTICS MARKET FOR TOPICAL, BY COUNTRY, 2021-2031 ($MILLION)
TABLE 26. PSORIASIS THERAPEUTICS MARKET, BY REGION, 2021-2031 ($MILLION)
TABLE 27. NORTH AMERICA PSORIASIS THERAPEUTICS MARKET, BY DRUG CLASS, 2021-2031 ($MILLION)
TABLE 28. NORTH AMERICA INTERLEUKIN INHIBITORS PSORIASIS THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
TABLE 29. NORTH AMERICA PSORIASIS THERAPEUTICS MARKET, BY TYPE, 2021-2031 ($MILLION)
TABLE 30. NORTH AMERICA PSORIASIS THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2031 ($MILLION)
TABLE 31. NORTH AMERICA PSORIASIS THERAPEUTICS MARKET, BY COUNTRY, 2021-2031 ($MILLION)
TABLE 32. U.S. PSORIASIS THERAPEUTICS MARKET, BY DRUG CLASS, 2021-2031 ($MILLION)
TABLE 33. U.S. PSORIASIS THERAPEUTICS MARKET, BY TYPE, 2021-2031 ($MILLION)
TABLE 34. U.S. PSORIASIS THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2031 ($MILLION)
TABLE 35. CANADA PSORIASIS THERAPEUTICS MARKET, BY DRUG CLASS, 2021-2031 ($MILLION)
TABLE 36. CANADA PSORIASIS THERAPEUTICS MARKET, BY TYPE, 2021-2031 ($MILLION)
TABLE 37. CANADA PSORIASIS THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2031 ($MILLION)
TABLE 38. MEXICO PSORIASIS THERAPEUTICS MARKET, BY DRUG CLASS, 2021-2031 ($MILLION)
TABLE 39. MEXICO PSORIASIS THERAPEUTICS MARKET, BY TYPE, 2021-2031 ($MILLION)
TABLE 40. MEXICO PSORIASIS THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2031 ($MILLION)
TABLE 41. EUROPE PSORIASIS THERAPEUTICS MARKET, BY DRUG CLASS, 2021-2031 ($MILLION)
TABLE 42. EUROPE INTERLEUKIN INHIBITORS PSORIASIS THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
TABLE 43. EUROPE PSORIASIS THERAPEUTICS MARKET, BY TYPE, 2021-2031 ($MILLION)
TABLE 44. EUROPE PSORIASIS THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2031 ($MILLION)
TABLE 45. EUROPE PSORIASIS THERAPEUTICS MARKET, BY COUNTRY, 2021-2031 ($MILLION)
TABLE 46. GERMANY PSORIASIS THERAPEUTICS MARKET, BY DRUG CLASS, 2021-2031 ($MILLION)
TABLE 47. GERMANY PSORIASIS THERAPEUTICS MARKET, BY TYPE, 2021-2031 ($MILLION)
TABLE 48. GERMANY PSORIASIS THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2031 ($MILLION)
TABLE 49. FRANCE PSORIASIS THERAPEUTICS MARKET, BY DRUG CLASS, 2021-2031 ($MILLION)
TABLE 50. FRANCE PSORIASIS THERAPEUTICS MARKET, BY TYPE, 2021-2031 ($MILLION)
TABLE 51. FRANCE PSORIASIS THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2031 ($MILLION)
TABLE 52. UK PSORIASIS THERAPEUTICS MARKET, BY DRUG CLASS, 2021-2031 ($MILLION)
TABLE 53. UK PSORIASIS THERAPEUTICS MARKET, BY TYPE, 2021-2031 ($MILLION)
TABLE 54. UK PSORIASIS THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2031 ($MILLION)
TABLE 55. ITALY PSORIASIS THERAPEUTICS MARKET, BY DRUG CLASS, 2021-2031 ($MILLION)
TABLE 56. ITALY PSORIASIS THERAPEUTICS MARKET, BY TYPE, 2021-2031 ($MILLION)
TABLE 57. ITALY PSORIASIS THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2031 ($MILLION)
TABLE 58. SPAIN PSORIASIS THERAPEUTICS MARKET, BY DRUG CLASS, 2021-2031 ($MILLION)
TABLE 59. SPAIN PSORIASIS THERAPEUTICS MARKET, BY TYPE, 2021-2031 ($MILLION)
TABLE 60. SPAIN PSORIASIS THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2031 ($MILLION)
TABLE 61. REST OF EUROPE PSORIASIS THERAPEUTICS MARKET, BY DRUG CLASS, 2021-2031 ($MILLION)
TABLE 62. REST OF EUROPE PSORIASIS THERAPEUTICS MARKET, BY TYPE, 2021-2031 ($MILLION)
TABLE 63. REST OF EUROPE PSORIASIS THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2031 ($MILLION)
TABLE 64. ASIA-PACIFIC PSORIASIS THERAPEUTICS MARKET, BY DRUG CLASS, 2021-2031 ($MILLION)
TABLE 65. ASIA-PACIFIC INTERLEUKIN INHIBITORS PSORIASIS THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
TABLE 66. ASIA-PACIFIC PSORIASIS THERAPEUTICS MARKET, BY TYPE, 2021-2031 ($MILLION)
TABLE 67. ASIA-PACIFIC PSORIASIS THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2031 ($MILLION)
TABLE 68. ASIA-PACIFIC PSORIASIS THERAPEUTICS MARKET, BY COUNTRY, 2021-2031 ($MILLION)
TABLE 69. JAPAN PSORIASIS THERAPEUTICS MARKET, BY DRUG CLASS, 2021-2031 ($MILLION)
TABLE 70. JAPAN PSORIASIS THERAPEUTICS MARKET, BY TYPE, 2021-2031 ($MILLION)
TABLE 71. JAPAN PSORIASIS THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2031 ($MILLION)
TABLE 72. CHINA PSORIASIS THERAPEUTICS MARKET, BY DRUG CLASS, 2021-2031 ($MILLION)
TABLE 73. CHINA PSORIASIS THERAPEUTICS MARKET, BY TYPE, 2021-2031 ($MILLION)
TABLE 74. CHINA PSORIASIS THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2031 ($MILLION)
TABLE 75. INDIA PSORIASIS THERAPEUTICS MARKET, BY DRUG CLASS, 2021-2031 ($MILLION)
TABLE 76. INDIA PSORIASIS THERAPEUTICS MARKET, BY TYPE, 2021-2031 ($MILLION)
TABLE 77. INDIA PSORIASIS THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2031 ($MILLION)
TABLE 78. AUSTRALIA PSORIASIS THERAPEUTICS MARKET, BY DRUG CLASS, 2021-2031 ($MILLION)
TABLE 79. AUSTRALIA PSORIASIS THERAPEUTICS MARKET, BY TYPE, 2021-2031 ($MILLION)
TABLE 80. AUSTRALIA PSORIASIS THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2031 ($MILLION)
TABLE 81. SOUTH KOREA PSORIASIS THERAPEUTICS MARKET, BY DRUG CLASS, 2021-2031 ($MILLION)
TABLE 82. SOUTH KOREA PSORIASIS THERAPEUTICS MARKET, BY TYPE, 2021-2031 ($MILLION)
TABLE 83. SOUTH KOREA PSORIASIS THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2031 ($MILLION)
TABLE 84. REST OF ASIA-PACIFIC PSORIASIS THERAPEUTICS MARKET, BY DRUG CLASS, 2021-2031 ($MILLION)
TABLE 85. REST OF ASIA-PACIFIC PSORIASIS THERAPEUTICS MARKET, BY TYPE, 2021-2031 ($MILLION)
TABLE 86. REST OF ASIA-PACIFIC PSORIASIS THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2031 ($MILLION)
TABLE 87. LAMEA PSORIASIS THERAPEUTICS MARKET, BY DRUG CLASS, 2021-2031 ($MILLION)
TABLE 88. LAMEA INTERLEUKIN INHIBITORS PSORIASIS THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
TABLE 89. LAMEA PSORIASIS THERAPEUTICS MARKET, BY TYPE, 2021-2031 ($MILLION)
TABLE 90. LAMEA PSORIASIS THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2031 ($MILLION)
TABLE 91. LAMEA PSORIASIS THERAPEUTICS MARKET, BY COUNTRY, 2021-2031 ($MILLION)
TABLE 92. BRAZIL PSORIASIS THERAPEUTICS MARKET, BY DRUG CLASS, 2021-2031 ($MILLION)
TABLE 93. BRAZIL PSORIASIS THERAPEUTICS MARKET, BY TYPE, 2021-2031 ($MILLION)
TABLE 94. BRAZIL PSORIASIS THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2031 ($MILLION)
TABLE 95. SAUDI ARABIA PSORIASIS THERAPEUTICS MARKET, BY DRUG CLASS, 2021-2031 ($MILLION)
TABLE 96. SAUDI ARABIA PSORIASIS THERAPEUTICS MARKET, BY TYPE, 2021-2031 ($MILLION)
TABLE 97. SAUDI ARABIA PSORIASIS THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2031 ($MILLION)
TABLE 98. SOUTH AFRICA PSORIASIS THERAPEUTICS MARKET, BY DRUG CLASS, 2021-2031 ($MILLION)
TABLE 99. SOUTH AFRICA PSORIASIS THERAPEUTICS MARKET, BY TYPE, 2021-2031 ($MILLION)
TABLE 100. SOUTH AFRICA PSORIASIS THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2031 ($MILLION)
TABLE 101. REST OF LAMEA PSORIASIS THERAPEUTICS MARKET, BY DRUG CLASS, 2021-2031 ($MILLION)
TABLE 102. REST OF LAMEA PSORIASIS THERAPEUTICS MARKET, BY TYPE, 2021-2031 ($MILLION)
TABLE 103. REST OF LAMEA PSORIASIS THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2031 ($MILLION)
TABLE 104.ABBVIE INC.: COMPANY SNAPSHOT
TABLE 105.ABBVIE INC.: OPERATING SEGMENTS
TABLE 106.ABBVIE INC.: PRODUCT PORTFOLIO
TABLE 107.ABBVIE INC.: NET SALES,
TABLE 108.ABBVIE INC.: KEY STRATERGIES
TABLE 109.AMGEN INC.: COMPANY SNAPSHOT
TABLE 110.AMGEN INC.: OPERATING SEGMENTS
TABLE 111.AMGEN INC.: PRODUCT PORTFOLIO
TABLE 112.AMGEN INC.: NET SALES,
TABLE 113.AMGEN INC.: KEY STRATERGIES
TABLE 114.BAUSCH HEALTH COMPANIES INC.: COMPANY SNAPSHOT
TABLE 115.BAUSCH HEALTH COMPANIES INC.: OPERATING SEGMENTS
TABLE 116.BAUSCH HEALTH COMPANIES INC.: PRODUCT PORTFOLIO
TABLE 117.BAUSCH HEALTH COMPANIES INC.: NET SALES,
TABLE 118.BAUSCH HEALTH COMPANIES INC.: KEY STRATERGIES
TABLE 119.ELI LILLY AND COMPANY: COMPANY SNAPSHOT
TABLE 120.ELI LILLY AND COMPANY: OPERATING SEGMENTS
TABLE 121.ELI LILLY AND COMPANY: PRODUCT PORTFOLIO
TABLE 122.ELI LILLY AND COMPANY: NET SALES,
TABLE 123.ELI LILLY AND COMPANY: KEY STRATERGIES
TABLE 124.JOHNSON AND JOHNSON: COMPANY SNAPSHOT
TABLE 125.JOHNSON AND JOHNSON: OPERATING SEGMENTS
TABLE 126.JOHNSON AND JOHNSON: PRODUCT PORTFOLIO
TABLE 127.JOHNSON AND JOHNSON: NET SALES,
TABLE 128.JOHNSON AND JOHNSON: KEY STRATERGIES
TABLE 129.LEO PHARMA: COMPANY SNAPSHOT
TABLE 130.LEO PHARMA: OPERATING SEGMENTS
TABLE 131.LEO PHARMA: PRODUCT PORTFOLIO
TABLE 132.LEO PHARMA: NET SALES,
TABLE 133.LEO PHARMA: KEY STRATERGIES
TABLE 134.NOVAN INC. (EPI HEALTH LLC): COMPANY SNAPSHOT
TABLE 135.NOVAN INC. (EPI HEALTH LLC): OPERATING SEGMENTS
TABLE 136.NOVAN INC. (EPI HEALTH LLC): PRODUCT PORTFOLIO
TABLE 137.NOVAN INC. (EPI HEALTH LLC): NET SALES,
TABLE 138.NOVAN INC. (EPI HEALTH LLC): KEY STRATERGIES
TABLE 139.NOVARTIS AG: COMPANY SNAPSHOT
TABLE 140.NOVARTIS AG: OPERATING SEGMENTS
TABLE 141.NOVARTIS AG: PRODUCT PORTFOLIO
TABLE 142.NOVARTIS AG: NET SALES,
TABLE 143.NOVARTIS AG: KEY STRATERGIES
TABLE 144.PFIZER INC.: COMPANY SNAPSHOT
TABLE 145.PFIZER INC.: OPERATING SEGMENTS
TABLE 146.PFIZER INC.: PRODUCT PORTFOLIO
TABLE 147.PFIZER INC.: NET SALES,
TABLE 148.PFIZER INC.: KEY STRATERGIES
TABLE 149.VIATRIS INC. (MYLAN NV): COMPANY SNAPSHOT
TABLE 150.VIATRIS INC. (MYLAN NV): OPERATING SEGMENTS
TABLE 151.VIATRIS INC. (MYLAN NV): PRODUCT PORTFOLIO
TABLE 152.VIATRIS INC. (MYLAN NV): NET SALES,
TABLE 153.VIATRIS INC. (MYLAN NV): KEY STRATERGIES
*** 免責事項 ***
https://www.globalresearch.co.jp/disclaimer/
